Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 352

1.

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer.

Gupta S, Neumeister V, McGuire J, Song YS, Acs B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL, Bossuyt V.

NPJ Breast Cancer. 2019 Aug 29;5:28. doi: 10.1038/s41523-019-0122-x. eCollection 2019.

2.

Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray.

Martinez-Morilla S, McGuire J, Gaule P, Moore L, Acs B, Cougot D, Gown AM, Yaziji H, Wang WL, Cartun RW, Hornick JL, Sholl LM, Qiu J, Mino-Kenudson M, Yi ES, Beasley MB, Merrick DT, Ambaye AB, Zhang ZJ, Walker J, Rimm DL.

Lab Invest. 2019 Aug 13. doi: 10.1038/s41374-019-0295-9. [Epub ahead of print]

PMID:
31409885
3.

Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology.

Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A.

Nat Rev Clin Oncol. 2019 Aug 9. doi: 10.1038/s41571-019-0252-y. [Epub ahead of print] Review.

PMID:
31399699
4.

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.

Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, Fujimoto D, Han G, Hirsch FR, Ilie M, Ionescu D, Li C, Munari E, Okuda K, Ratcliffe MJ, Rimm DL, Ross C, Røge R, Scheel AH, Soo RA, Swanson PE, Tretiakova M, To KF, Vainer GW, Wang H, Xu Z, Zielinski D, Tsao MS.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0327-4. [Epub ahead of print] Review.

PMID:
31383961
5.

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.

Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL.

J Immunother Cancer. 2019 Jul 23;7(1):194. doi: 10.1186/s40425-019-0675-0.

6.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1549. [Epub ahead of print]

PMID:
31318407
7.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L.

Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.

8.

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.

Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL.

Clin Cancer Res. 2019 Sep 15;25(18):5503-5512. doi: 10.1158/1078-0432.CCR-19-0104. Epub 2019 Jun 12.

PMID:
31189645
9.

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.

Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty.

Eur J Cancer. 2019 Jun;114:128-136. doi: 10.1016/j.ejca.2019.03.025. Epub 2019 May 3.

PMID:
31060925
10.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
11.

Corrigendum to "Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma" [Oral Oncol. 86 (2018) 278-287].

Hartman DJ, Ahmed FS, Ferris RL, Rimm DL, Pantanowitz L.

Oral Oncol. 2019 Jun;93:129. doi: 10.1016/j.oraloncology.2019.04.016. Epub 2019 Apr 30. No abstract available.

PMID:
31053366
12.

False-positive pathology: improving reproducibility with the next generation of pathologists.

Mazer BL, Homer RJ, Rimm DL.

Lab Invest. 2019 Sep;99(9):1260-1265. doi: 10.1038/s41374-019-0257-2. Epub 2019 Apr 24.

PMID:
31019290
13.

Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee.

Moncur JT, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Kim AS.

Arch Pathol Lab Med. 2019 Apr 10. doi: 10.5858/arpa.2018-0396-CP. [Epub ahead of print]

PMID:
30969158
14.

Immune Checkpoint Inhibitor-Associated Pericarditis.

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL.

J Thorac Oncol. 2019 Jun;14(6):1102-1108. doi: 10.1016/j.jtho.2019.02.026. Epub 2019 Mar 7.

PMID:
30851443
15.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).

Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA.

J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1.

16.

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L.

Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4.

PMID:
30833750
17.

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS.

Clin Cancer Res. 2019 Aug 1;25(15):4592-4602. doi: 10.1158/1078-0432.CCR-18-1538. Epub 2019 Mar 1. Review.

PMID:
30824587
18.

Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.

Carvajal-Hausdorf DE, Patsenker J, Stanton KP, Villarroel-Espindola F, Esch A, Montgomery RR, Psyrri A, Kalogeras KT, Kotoula V, Foutzilas G, Schalper KA, Kluger Y, Rimm DL.

Clin Cancer Res. 2019 May 15;25(10):3054-3062. doi: 10.1158/1078-0432.CCR-18-2599. Epub 2019 Feb 22.

PMID:
30796036
19.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
20.

A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.

Taylor CR, Jadhav AP, Gholap A, Kamble G, Huang J, Gown A, Doshi I, Rimm DL.

Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. doi: 10.1097/PAI.0000000000000737.

PMID:
30640753
21.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy530. [Epub ahead of print] No abstract available.

22.

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.

Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL.

Clin Cancer Res. 2019 Apr 15;25(8):2442-2449. doi: 10.1158/1078-0432.CCR-18-2652. Epub 2019 Jan 7.

PMID:
30617133
23.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

24.

Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.

Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL.

NPJ Breast Cancer. 2018 Dec 10;4:40. doi: 10.1038/s41523-018-0095-1. eCollection 2018.

25.

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.

Pelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL.

Breast Cancer Res. 2018 Dec 17;20(1):154. doi: 10.1186/s13058-018-1076-x.

26.

Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.

Hartman DJ, Ahmad F, Ferris RL, Rimm DL, Pantanowitz L.

Oral Oncol. 2018 Nov;86:278-287. doi: 10.1016/j.oraloncology.2018.10.005. Epub 2018 Oct 11. Erratum in: Oral Oncol. 2019 Jun;93:129.

PMID:
30409313
27.

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.

Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.

J Thorac Oncol. 2018 Dec;13(12):1884-1896. doi: 10.1016/j.jtho.2018.09.012. Epub 2018 Sep 26.

PMID:
30267840
28.

Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens.

Rawat RR, Ruderman D, Macklin P, Rimm DL, Agus DB.

NPJ Breast Cancer. 2018 Sep 4;4:32. doi: 10.1038/s41523-018-0084-4. eCollection 2018.

29.

Immunological differences between primary and metastatic breast cancer.

Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L.

Ann Oncol. 2018 Nov 1;29(11):2232-2239. doi: 10.1093/annonc/mdy399.

PMID:
30203045
30.

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.

Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos K, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A.

Clin Cancer Res. 2019 Mar 1;25(5):1526-1534. doi: 10.1158/1078-0432.CCR-18-2013. Epub 2018 Sep 10.

PMID:
30201760
31.

Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study.

Acs B, Pelekanou V, Bai Y, Martinez-Morilla S, Toki M, Leung SCY, Nielsen TO, Rimm DL.

Lab Invest. 2019 Jan;99(1):107-117. doi: 10.1038/s41374-018-0123-7. Epub 2018 Sep 4.

PMID:
30181553
32.

An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer.

Rimm DL, Leung SCY, McShane LM, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere EK, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga EN, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M.

Mod Pathol. 2019 Jan;32(1):59-69. doi: 10.1038/s41379-018-0109-4. Epub 2018 Aug 24.

PMID:
30143750
33.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.

Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8.

34.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
35.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

36.

Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.

Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL.

Lab Invest. 2018 Aug;98(8):1076-1083. doi: 10.1038/s41374-018-0064-1. Epub 2018 Jun 1.

37.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.

Ann Oncol. 2018 Oct 1;29(10):2152. doi: 10.1093/annonc/mdx805. No abstract available.

38.

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.

Pelekanou V, Barlow WE, Nahleh ZA, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L.

Mol Cancer Ther. 2018 Jun;17(6):1324-1331. doi: 10.1158/1535-7163.MCT-17-1005. Epub 2018 Mar 27.

39.

An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients.

Moore LM, Wilkinson R, Altan M, Toki M, Carvajal-Hausdorf DE, McGuire J, Ehrlich BE, Rimm DL.

NPJ Breast Cancer. 2018 Mar 12;4:6. doi: 10.1038/s41523-018-0057-7. eCollection 2018.

40.

Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity.

Correa BRS, Hu J, Penalva LOF, Schlegel R, Rimm DL, Galante PAF, Agarwal S.

Sci Rep. 2018 Mar 6;8(1):4097. doi: 10.1038/s41598-018-22427-1.

41.

Not Just Digital Pathology, Intelligent Digital Pathology.

Acs B, Rimm DL.

JAMA Oncol. 2018 Mar 1;4(3):403-404. doi: 10.1001/jamaoncol.2017.5449. No abstract available.

PMID:
29392271
42.

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.

Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner ES, Schwartz PE, Santin AD.

Clin Cancer Res. 2018 Jul 15;24(14):3282-3291. doi: 10.1158/1078-0432.CCR-17-1805. Epub 2018 Jan 19.

43.

Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.

Kim AS, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Moncur JT.

JAMA Oncol. 2018 Jun 1;4(6):838-841. doi: 10.1001/jamaoncol.2017.4021.

44.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

45.

Worldwide Frequency of Commonly Detected EGFR Mutations.

Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, Rimm DL.

Arch Pathol Lab Med. 2018 Feb;142(2):163-167. doi: 10.5858/arpa.2016-0579-CP. Epub 2017 Nov 6.

PMID:
29106293
46.

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL.

J Immunother Cancer. 2017 Oct 17;5(1):81. doi: 10.1186/s40425-017-0285-7.

47.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

48.

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Sep 25;19(1):109. doi: 10.1186/s13058-017-0898-2. No abstract available.

49.

High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.

Wasserman BE, Carvajal-Hausdorf DE, Ho K, Wong W, Wu N, Chu VC, Lai EW, Weidler JM, Bates M, Neumeister V, Rimm DL.

Lab Invest. 2017 Dec;97(12):1521-1526. doi: 10.1038/labinvest.2017.93. Epub 2017 Sep 11.

50.

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Aug 7;19(1):91. doi: 10.1186/s13058-017-0884-8. Erratum in: Breast Cancer Res. 2017 Sep 25;19(1):109.

Supplemental Content

Support Center